Efficacy of theophylline in patients affected by low-adenosine syncope
Michele Brignole, Diana Solari, Matteo Iori, Nicola Bottoni, Régis Guieu, J. C. Deharo

To cite this version:
Efficacy of theophylline in patients affected by low-adenosine syncope

Michele Brignole, MD¹, Diana Solari, MD¹, Matteo Iori, MD², Nicola Bottoni², Regis Guieu, MD³, Jean Claude Deharo, MD³

1. Department of Cardiology, Ospedali del Tigullio, Lavagna, GE
2. Department of Cardiology, Arcispedale S. Maria Nuova, Reggio Emilia
3. UMR MD2, Aix Marseille University, and Institute of Biological research of the French Army (IRBA), Marseille, France

Total word count: 2583 (excluding front page)

Statement. We declare no relationship with industry. The study was not funded.

Corresponding Author:
Michele Brignole, MD,
Department of Cardiology, Ospedali del Tigullio, via don Bobbio 25, 16033 Lavagna, Italy.
Telephone: +39 0185329567
Email: mbrignole@asl4.liguria.it
Abstract

**Background.** Adenosine, an ATP derivative, may be implicated in some kinds of unexplained syncope. In patients with normal heart, normal ECG and recurrent sudden-onset syncope without prodromes have been shown to present with lowplasmatic adenosine levels and a high susceptibility to exogenous adenosine. The term “low-adenosine syncope” has been launched to describe this distinct clinical entity.

**Objectives.** We decided to investigate whether chronic treatment of these patients with theophylline, a non-selective adenosine receptor antagonist, results in clinical benefit.

**Methods.** We report on the prolonged clinical observation of 6 “low-adenosine” syncope patients (mean age 50±20 years, 4 females) treated with oral theophylline within the therapeutic range of 12-18 μg/ml. We were able to make an intrapatient comparison between a period with and a period without theophylline therapy.

**Results.** In five patients, symptoms disappeared and the number of prolonged asystolic pauses detected by implantable loop recorder (ILR) fell impressively from a median of 1.11 per month (interquartile range 0.4 -1.8) during 13 months of no-treatment (range 2-36) to 0 per month(0-0.7) during 20 months of theophylline treatment (range 6-120). The 6th patient, was unresponsive to theophylline therapy, and a different mechanism of syncope was hypothesized.

**Conclusion.** In this small series of highlyselected patients affected by syncope with low circulating adenosine levels, theophylline proved to be an effective therapy in most patients. The logical inference is that the adenosine pathway has a causal role in the mechanism of syncope in such patients.
Introduction

Adenosine, an ATP derivative, may be implicated in some kinds of unexplained syncope. Patients with unexplained syncope of sudden onset, a normal heart and normal ECG (so-called “unexplained syncope, no prodromes and normal heart”) have been shown to be different from vasovagal syncope patients (1,2). Rather, their clinical and biological features are close to those observed in patients affected by idiopathic paroxysmal AV block (3). Patients with syncope without prodromes and normal heart and patients with idiopathic AV block have an adenosine profile which is opposite to that observed in vasovagal syncope patients and is characterized by very low plasmatic adenosine values, low expression of A2A adenosine receptors and a high induction rate of transient complete heart block during exogenous injections of adenosine (4). Unlike in vasovagal syncope patients, tilt testing is usually negative (4). These forms of syncope have been labelled “low-adenosine syncope” (1) and this terminology will be used throughout this manuscript.

Since patients with low plasma adenosine levels are highly susceptible to exogenous and endogenous adenosine (2-6) we wanted to investigate if treatment with theophylline, a non-selective adenosine receptor antagonist, should result in prevention of syncopal recurrences. We found the opportunity to test this hypothesis in a highly selected subset of patients who will be described in this manuscript.

Description of patients

We report on the prolonged clinical observation of 6 “low-adenosine” syncope patients (mean age 50±20 years, 4 females) treated with oral theophylline within the therapeutic range of 12-18μg/ml. The patients had common major clinical features: 1) a long-standing history (median 8 years, range 3-30 years) of recurrent unexplained syncopes without prodromes, normal heart and normal ECG; and 2) baseline values of plasmatic adenosine (0.11±0.03 μmol/L) well below the 5th percentile of the value of normal subjects (0.40 μmol/L) (4). Multiple episodes of paroxysmal AV block and sinus-atrial arrest were documented at the time of (pre)syncopes in 4 and 1 patients, respectively; in another patient, documentation of the mechanism was lacking, as no ECG monitoring was active at the time of symptoms. Patient characteristics are listed in Table 1.

We had the opportunity to perform an intrapatient comparison between a period with and a period without theophylline therapy with the support of prolonged ECG monitoring in the majority of them (Table 2). The follow-up of all patients is updated to July 2015.

Specifically:

- patient #1 was seen in 1995 and followed up for 20 years. In 1995, Holter monitoring fortuitously recorded idiopathic paroxysmal AV block, which was reproduced on the adenosine triphosphate test (ATP test). For the next 10 years, she underwent theophylline therapy, during which time she had no syncopal recurrences. In 2005, soon after discontinuing theophylline, she had a syncopal recurrence, for which she received an implantable loop recorder (ILR); over the next 3 years, 2 further episodes of idiopathic paroxysmal AV block
with long asystolic pauses up to 22 s were documented. In 2008, she received a permanent pacemaker and has remained asymptomatic since that time.

- patient #2 participated in a 2-period cross-over trial (Off-On-Off-On therapy) under ILR monitoring: episodes of idiopathic paroxysmal AV block decreased from 19 (max pause 7 s) off therapy to 4 (max pause 3 s) on therapy (Figure 1 and Figure 2 panels A, B and C).
- patient #3 had 8 syncopes in the 2 years off therapy and no recurrence during the subsequent 2 years on therapy. Only when she started theophylline did she receive an ILR, which never recorded any arrhythmias.
- in patient #4, episodes of idiopathic paroxysmal AV block dropped from 27 (max pause 7 s) off therapy to 0 on therapy (Figure 3).
- patient #5 was the only patient who had a sinus-atrial arrest documented with an ILR: two consecutive pauses due to sinus arrest of 3 s and 6 s were preceded by few beats of slowing of sinus rate; he remained free of symptoms and arrhythmias during the 20 months of theophylline therapy.
- we also report the case of a woman (case #6) who had very frequent (daily) pre-syncopes during a 3-year observation period; on several occasions, she underwent 24-hour Holter monitoring, which, on each occasion, detected multiple episodes of paroxysmal asystolic AV block preceded and followed by PR interval prolongation and 2nd degree AV block (Figure 4). Since the patient refused pacemaker implantation, she was treated with oral theophylline 600 mg/day for 1.5 months: although her symptoms persisted, the episodes of asystolic AV block declined from 14 (longest pause 9.2 s) on pre-therapy Holter monitoring to 7 (longest 6.7 s) on monitoring during theophylline.

To summarize, in 5 patients, who presented with asystole during long-term continuous ECG monitoring, symptoms disappeared and ECG-documented pauses were impressively reduced during the theophylline period in comparison with the no-treatment period. The 6th patient was unresponsive or hypo-responsive to theophylline therapy (Table 2).

**Discussion**

In this series of case reports, theophylline appeared effective in five out of six patients with recurrent sudden onset (pre)syncope and who presented with the common biological characteristic of low circulating adenosine levels. Since theophylline is a non-selective antagonist of purinergic receptors, we hypothesize that purinergic receptors are involved in the mechanism of syncope in such patients.

Like other methylated xanthine derivatives, theophylline is a non-selective A1 and A2 adenosine-receptor antagonist (10). When plasma adenosine values are far below the constant of dissociation (KD) value of 0.7µM for A1 adenosine receptors (A1 R) (5), as in our patients, many A1 R are free. A2 R are known to be located within the AV node and, to a lesser extent, in the sinus node, and therefore their activation may cause syncope as a result of prolonged asystolic pauses due to AV block or sinus arrest (2,3,4,6,11). Theophylline is able to saturate A1 R, thus preventing an acute increase in plasmatic adenosine (e.g., in the case of myocardial hypoxia or during reflex beta-adrenergic stimulation [6,11]) from recruiting a sufficient number of receptors to cause AV
block or sinus-atrial arrest. In addition, as theophylline is also an almost equally potent antagonist of A2 receptors, which are located in the vessels and cause vasodilation, a synergic antagonist action of this drug may also be possible. Conversely, when baseline plasmaadenosine level is high, as in patients with vasovagal syncope or positive tilt testing, most high-affinity A1 R are already saturated, and probably desensitized; thus, adenosine release is unlikely to have an effect on A1 receptors and consequently on heart rate (4,7). Thus, from a pathophysiological point of view, xanthine derivatives may probably be less effective, owing to the high dose necessary to displace high concentrations of adenosine from its receptors. Indeed, in an acute study (12) theophylline was ineffective in patients with tilt-induced vasovagal syncope whereas it was partially effective in preventing dipyridamole-induced syncope.

The above considerations could explain the variable efficacy of theophylline therapy reported in the literature in the absence of plasmatic adenosine assay. In 11 patients with recurrent unexplained syncopes and positive ATP test - which suggests an overlap with low adenosine patients - syncope recurred in 2 patients (15%) during a mean follow-up of 13 months (13). The few small observational studies existing in the literature in patients with vasovagal syncope report a recurrence rate ranging between 12% and 22% (14,15,16). Finally, in a randomized controlled trial (17), theophylline was ineffective in preventing syncope in patients affected by intrinsic sick sinus syndrome compared with no treatment arm.

Some patients in our report differ from the others. Patient #3 had undocumented syncope, the efficacy of theophylline could only be argued from the dramatic disappearance of symptoms as soon as she started the therapy. Patient #5 presented with sinus arrest and not AV block and had a cardioinhibitory response with tilt test which suggests a vasovagal mechanism. On the other hand the clinical presentation of syncopes without prodromes (consistent with the ECG documentation of sudden onset sinus arrest) and low plasmatic adenosine are common features with the other patients and theophylline was effective. A joint involvement of both acetylcholinergic and purinergic pathways in this case is possible and has a solid pathophysiologial (6) and clinical (7,18) background in the literature. Patient #6 was not responsive to theophylline although she had low adenosine plasma levels; the very frequent episodes of paroxysmal AV block observed on each 24-hour Holter recording have features compatible with vagally-induced (8,9) rather than idiopathic AV block (3). However, this case was reported here since it shared the common biological pattern of low plasma adenosine syncope.

Limitations

The present report has several limitations, mainly due to the small number of patients described and the lack of a homogeneous data collection. Nevertheless, these limitations are partly overcome by the long follow-up – up to several years – the electrocardiographic documentation of syncope in most of the patients and the intrapatient control comparison.

The present report lacks of a formal comparison with patients with documented episodes paroxysmal AV block and sinus-atrial arrest of known etiology. We reviewed our adenosine database and we found 10 patients with a clinically established diagnosis of reflex syncope who had an ILR documentation of asystolic syncope. In contrast with the patients of the present report, all 9 vasovagal patients had progressive sinus bradycardia followed by sinus arrest; they had high
adenosine and high expression of A2A adenosine receptors. The patient with swallowing syncope had recurrent paroxysmal AV block similar to our patient #6 but normal adenosine value (Table 3). Furthermore, we found 4 patients who had an intrinsic paroxysmal AV block due to degenerative disease of AV conduction system. These patients had normal adenosine values (Table 3). Thus, low adenosine is a typical feature of patients with unexplained syncope, no prodrome and normal heart. We argue that in such patients theophylline has little rationale to be as effective as in our patients.

**Conclusion and perspectives**

In conclusion, theophylline seems to be able to prevent syncopal recurrences and asystolic events in patients with low-adenosine syncope, and may be considered as an alternative to permanent pacing therapy in such patients. This study provides the rationale for planning a randomized controlled trial aimed at confirming or refuting these results. At present it is unknown how many patients with unexplained syncope are actually “low adenosine” patients who could benefit of theophylline therapy. In the ISSUE 2 and ISSUE 3 studies [19,20], which enrolled patients with suspected or certain neurally-mediated syncope (prodromes were absent in about a half of them), an idiopathic-like paroxysmal AV block was observed in 8% of patients who had a ILR documentation of syncope and accounted for 22% of those of had an asystolic event. It is possible that some of these patients were “low adenosine” patients.
References


Figure 1

Patient #2, affected by idiopathic paroxysmal V block. This patient participated in a 2-period cross-over trial (Off-On-Off-On therapy) under ILR monitoring for a total of 25 months. The histograms show the numbers of episodes per month. Episodes of idiopathic paroxysmal AV block decreased from 19 (max pause 7 s) off therapy to 4 (max pause 3 s) on therapy.
Figure 2

A)  
OFF theophylline (Aug 26, 2013)

B)  
ON theophylline (Jul 29, 2014)

Case #2, M, 72 yrs
Case #2, M, 72 yrs

OFF theophylline (Dec 31, 2014)

Figure 2. Same patient as figure 1. The panels show examples of typical idiopathic paroxysmal AV block characterized by sudden-onset AV block without R-R cycle changes and constant PR interval. **Panel A**: Recording during the first period Off therapy: 4 consecutive P waves are blocked (pause of 7 s) and are followed by a conducted beat and then by another single blocked P wave. **Panel B**: Recording during the first period On therapy: the blocked P waves are reduced to 2 and the maximum pause is of 3 s. **Panel C**: Recording during the second period Off therapy. The episode resembles that of the first Off period: 6 consecutive P waves are blocked (pause of 6 s) and are followed by a conducted beat and then by another single blocked P wave.
**Figure 3**

*Patient #4, affected by idiopathic paroxysmal V block. This patient participated in a crossover trial (Off-On therapy) under ILR monitoring for a total of 20 months. The histograms show the numbers of episodes per month. A total of 27 episodes of idiopathic paroxysmal AV block (max pause 7 s) occurred in the 13-month period off therapy; episodes disappeared completely as soon as the patient started theophylline therapy.*
Figure 4. The continuous ECG tracing (lead II) shows an episode of paroxysmal AV block. In this patient, too, AV block occurred without P-P cycle changes; unlike case #4, however, the PR interval lengthens before block, from 0.20 s to 0.28 s in the beat immediately preceding the asystolic pause. Furthermore, the asystolic pause is followed by 2:1 AV block and then 1st degree AV block with prolonged PR interval up to 0.36 s in the conducted beats. PR prolongation is suggestive of vagal AV block (8,9) rather than adenosine AV block or idiopathic AV block (3). For comparison, see case 2, figure 1.
Table 1. Characteristics of the 6 “low-adenosine” patients who were treated with theophylline

<table>
<thead>
<tr>
<th>No, gender, age</th>
<th>ECG documentation of the index event, (total duration/longest pause) *</th>
<th>Adenosine plasmatic level, μmol/L (normal range: 0.40-0.78)</th>
<th>A2A adenosine receptor expression, AU (normal range: 0.40-0.80)</th>
<th>Adenosine i.v. test, max pause</th>
<th>Tilt table test</th>
<th>Carotid sinus massage</th>
<th>Electro-physiological study</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1. F, 50 yrs</td>
<td>Idiopathic AVB (34/22 s)</td>
<td>0.12</td>
<td>0.20</td>
<td>11 s</td>
<td>negative</td>
<td>negative</td>
<td>negative</td>
</tr>
<tr>
<td>#2. M, 72 yrs</td>
<td>Idiopathic AVB (11/7 s)</td>
<td>0.09</td>
<td>0.50</td>
<td>neg</td>
<td>negative</td>
<td>negative</td>
<td>negative</td>
</tr>
<tr>
<td>#3. F, 20 yrs</td>
<td>none (ILR only with theophylline)</td>
<td>0.09</td>
<td>0.55</td>
<td>5.4 s</td>
<td>negative</td>
<td>np</td>
<td>negative</td>
</tr>
<tr>
<td>#4. F, 71 yrs</td>
<td>Idiopathic AVB (24/7 s)</td>
<td>0.10</td>
<td>np</td>
<td>7 s</td>
<td>positive mixed</td>
<td>negative</td>
<td>np</td>
</tr>
<tr>
<td>#5. M, 41 yrs</td>
<td>Sinus arrest (18/6 s)</td>
<td>0.18</td>
<td>0.80</td>
<td>7.4 s</td>
<td>positive cardioinhib.</td>
<td>negative</td>
<td>np</td>
</tr>
<tr>
<td>#6. F, 52 yrs</td>
<td>Paroxysmal AVB (-9/-9 s)</td>
<td>0.10</td>
<td>0.45</td>
<td>7.6 s</td>
<td>negative</td>
<td>negative</td>
<td>negative</td>
</tr>
</tbody>
</table>

* documentation with prolonged monitoring by means of implantable loop recorder (ILR) in cases 1, 2, 4 and 5 and Holter monitoring in case 6

AVB = atrioventricular block; np = not performed

Adenosine plasma level was evaluated by means of high-performance liquid chromatography, as previously described [2]. Adenosine A2A receptor expression was evaluated by western blot, as previously described (7). The normal ranges are between the 5th and 95th percentiles of the values recorded in healthy control subjects (4).
Table 2. Comparative effect on outcome in 5 patients who responded to theophylline and the one who did not

<table>
<thead>
<tr>
<th>Pt no.</th>
<th>History of syncope before diagnosis</th>
<th>Observation without therapy</th>
<th>Observation during theophylline therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Duration, years</td>
<td>no. of episodes</td>
<td>Months</td>
</tr>
<tr>
<td>#1</td>
<td>30</td>
<td>20</td>
<td>36</td>
</tr>
<tr>
<td>#2</td>
<td>12</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>#3</td>
<td>18</td>
<td>40</td>
<td>24</td>
</tr>
<tr>
<td>#4</td>
<td>1</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td>#5</td>
<td>3</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>12 (3-18)</td>
<td>5 (2-20)</td>
<td>13 (11-24)</td>
</tr>
<tr>
<td>#6</td>
<td>2.5</td>
<td>Frequent pre-syncopes</td>
<td>6</td>
</tr>
</tbody>
</table>

* observation with prolonged monitoring by means of implantable loop recorder (ILR) in cases 1-5 and Holter monitoring in case 6
np = not performed; IQR = interquartile range

Wilcoxon matched-pairs signed rank test: too few cases to use this test
Table 3. Comparative clinical and laboratory findings in a control group of patients affected by ECG-documented asystolic vasovagal/situational syncope or intrinsic cardiac paroxysmal atrioventricular block

<table>
<thead>
<tr>
<th>Pat. number gender, age</th>
<th>Etiology</th>
<th>Clinical features</th>
<th>History of syncope (duration, yrs / number of episodes)</th>
<th>ECG documentation of the index event, (longest pause)</th>
<th>Adenosine plasmatic level, μmol/L (normal range: 0.40-0.78)</th>
<th>A2 A adenosine receptor expression, AU (normal range: 0.40-0.80)</th>
<th>Tilt testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1. M, 69 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>1 / 5</td>
<td>Brady + Sinus arrest (8 s)</td>
<td>0.90</td>
<td>1.1</td>
<td>positive mixed</td>
<td></td>
</tr>
<tr>
<td>#2. M, 32 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>Since childhood / 20</td>
<td>Brady + Sinus arrest (16 s)</td>
<td>1.20</td>
<td>-</td>
<td>positive asystole</td>
<td></td>
</tr>
<tr>
<td>#3. F, 71 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>Since childhood / 1 last year</td>
<td>Brady + Sinus arrest (5 s)</td>
<td>1.9/1.2</td>
<td>0.98</td>
<td>positive mixed</td>
<td></td>
</tr>
<tr>
<td>#4. F, 68 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>Since childhood / 7 last year</td>
<td>Brady + Sinus arrest (38 s)</td>
<td>1.39</td>
<td>1.4/1.5</td>
<td>positive mixed</td>
<td></td>
</tr>
<tr>
<td>#5. M, 44 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>5 / 3</td>
<td>Brady + Sinus arrest (6.5 s)</td>
<td>1.67</td>
<td>-</td>
<td>negative</td>
<td></td>
</tr>
<tr>
<td>#6. M, 53 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>5 / 3</td>
<td>Brady + Sinus arrest (3.5 s)</td>
<td>0.97</td>
<td>-</td>
<td>negative</td>
<td></td>
</tr>
<tr>
<td>#7. M, 59 yrs Reflex</td>
<td>VVS (typical long prodromes)</td>
<td>14 / 8</td>
<td>Brady + Sinus arrest (5.5 s)</td>
<td>1.24</td>
<td>-</td>
<td>negative</td>
<td></td>
</tr>
<tr>
<td>#8. F, 83 yrs Reflex</td>
<td>Post-prandial</td>
<td>4 / 4</td>
<td>Bradycardia 30 bpm</td>
<td>0.98</td>
<td>-</td>
<td>positive asystole</td>
<td></td>
</tr>
<tr>
<td>#9. M, 43 yrs Reflex</td>
<td>Atypical VVS (atypical short prodromes, supine, long recovery)</td>
<td>1 / 5</td>
<td>Brady + AVB + sinus arrest (42 s)</td>
<td>1.90</td>
<td>-</td>
<td>negative</td>
<td></td>
</tr>
<tr>
<td>#10. F, 33 yrs Reflex</td>
<td>Swallowing syncope (produced with active swallow)</td>
<td>Since childhood / &gt;20</td>
<td>Daily narrow QRS AVB (4 s)</td>
<td>0.6</td>
<td>0.45</td>
<td>positive mixed</td>
<td></td>
</tr>
<tr>
<td>#11. M, 80 yrs Cardiac</td>
<td>Intrinsic AV conduction disease</td>
<td>No</td>
<td>Narrow QRS paroxysmal AVB</td>
<td>0.45</td>
<td>-</td>
<td>not performed</td>
<td></td>
</tr>
<tr>
<td>#12. F, 79 yrs Cardiac</td>
<td>Intrinsic AV conduction disease</td>
<td>0.1/1</td>
<td>Narrow QRS paroxysmal AVB</td>
<td>0.70</td>
<td>-</td>
<td>not performed</td>
<td></td>
</tr>
<tr>
<td>#13. F, 79 yrs Cardiac</td>
<td>Intrinsic AV conduction disease and aortic stenosis</td>
<td>No</td>
<td>Wide QRS paroxysmal AVB</td>
<td>0.45</td>
<td>-</td>
<td>not performed</td>
<td></td>
</tr>
<tr>
<td>#13. F, 84 yrs Cardiac</td>
<td>Intrinsic AV conduction disease and hypertension</td>
<td>No</td>
<td>Narrow QRS paroxysmal AVB</td>
<td>0.35</td>
<td>-</td>
<td>not performed</td>
<td></td>
</tr>
</tbody>
</table>